Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | PNP | P00491 | 1/20 | 0.55 |
| ▸ | EDNRA | P25101 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | HBB | P68871 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | TK1 | P04183 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7688901 | 0.85 | TK1 (0.70) | TSHRUSP2PNPEDNRAHTR2A | |
| SCHEMBL12786366 | 0.79 | PNP (0.70) | TSHRUSP2PNPEDNRAHTR2A | |
| SCHEMBL16082172 | 0.78 | PNP (0.72) | TSHRUSP2PNPEDNRAHTR2A | |
| SCHEMBL10649363 | 0.77 | PNP (0.64) | TSHRUSP2PNPEDNRAHTR2A | |
| SCHEMBL8444939 | 0.76 | MEN1 (0.80) | TSHRUSP2PNPEDNRAHTR2A | |
| Hexadecylamine SCHEMBL14742878 | 0.75 | PNP (0.78) | TSHRUSP2PNPEDNRAHTR2A | |
| Pentadecylamine SCHEMBL16060176 | 0.75 | PNP (0.78) | TSHRUSP2PNPEDNRAHTR2A | |
| SCHEMBL1177923 | 0.75 | MEN1 (0.60) | TSHRUSP2PNPEDNRAHTR2A | |
| SCHEMBL12786344 | 0.74 | PNP (0.77) | TSHRUSP2PNPEDNRAHTR2A | |
| SCHEMBL22875772 | 0.74 | MEN1 (0.64) | TSHRUSP2PNPEDNRAHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10940150-B2 | Thymine derivatives and quinazoline-dione derivatives for the inhibition of HSP27 | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2021-03-09 | — | — | US | disclosed |
| US-10940150-B2 | Thymine derivatives and quinazoline-dione derivatives for the inhibition of HSP27 | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2021-03-09 | — | — | US | disclosed |
| US-20180207160-A1 | THYMINE DERIVATIVES AND QUINAZOLINE-DIONE DERIVATIVES FOR THE INHIBITION OF HSP27 | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2018-07-26 | — | — | US | disclosed |
| US-20180207160-A1 | THYMINE DERIVATIVES AND QUINAZOLINE-DIONE DERIVATIVES FOR THE INHIBITION OF HSP27 | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2018-07-26 | — | — | US | disclosed |
| US-20170216297-A1 | EFFICIENT INHIBITION OF HSP27 | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2017-08-03 | — | — | US | disclosed |
| US-20170216297-A1 | EFFICIENT INHIBITION OF HSP27 | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2017-08-03 | — | — | US | disclosed |
| EP-3174541-A1 | THYMINE DERIVATIVES AND QUINAZOLINE-DIONE DERIVATIVES FOR THE INHIBITION OF HSP27 | Technische Universität Dresden (DE) | 2017-06-07 | — | — | EP | disclosed |
| EP-3174545-A1 | EFFICIENT INHIBITION OF HSP27 | Technische Universität Dresden (DE) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016267-A1 | EFFICIENT INHIBITION OF HSP27 | Technische Universität Dresden (DE) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016016268-A1 | THYMINE DERIVATIVES AND QUINAZOLINE-DIONE DERIVATIVES FOR THE INHIBITION OF HSP27 | Technische Universität Dresden (DE) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016016268-A1 | THYMINE DERIVATIVES AND QUINAZOLINE-DIONE DERIVATIVES FOR THE INHIBITION OF HSP27 | Technische Universität Dresden (DE) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016016267-A1 | EFFICIENT INHIBITION OF HSP27 | Technische Universität Dresden (DE) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207160-A1 | THYMINE DERIVATIVES AND QUINAZOLINE-DIONE DERIVATIVES FOR THE INHIBITION OF HSP27 | HSPB1, HSP90B1, HSP90AB1 | POLA1 727/4885TSHR 3759/4885USP2 2996/4885 |
| US-20170216297-A1 | EFFICIENT INHIBITION OF HSP27 | HSPB1, HSP90AB2P, HSP90B1 | POLA1 1240/4885TSHR 4689/4885USP2 1096/4885 |
| US-10940150-B2 | Thymine derivatives and quinazoline-dione derivatives for the inhibition of HSP27 | HSPB1, HSP90B1, HSP90AB1 | POLA1 727/4885TSHR 3759/4885USP2 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.